May 8, 2024 4:30 pm EDT Largest Prospective Study to Date Further Supports Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with DecisionDx-UM Class Result
May 3, 2024 7:00 am EDT DecisionDx®-SCC Significantly Improves Prediction Accuracy of Metastatic Events after Mohs Surgery in New Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Tumors of the Head and Neck
Apr 30, 2024 4:30 pm EDT Castle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood’s Designation as a Sun Safe Leadership Model City by IMPACT Melanoma
Apr 11, 2024 7:00 am EDT Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024
Apr 10, 2024 5:00 pm EDT Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations
Apr 10, 2024 7:00 am EDT Castle Biosciences’ Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year
Apr 4, 2024 4:30 pm EDT Presentations at EADO Highlight Potential Impact of Castle Biosciences’ DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer
Apr 2, 2024 7:00 am EDT Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
